Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

NCT01517373 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo
DRUG: PF-04937319 10 mg
DRUG: PF-04937319 50 mg
DRUG: PF-04937319 100 mg
DRUG: Glimepiride

Sponsor

Pfizer